*Sponsored
Market Crux Initiates Coverage On (ENVB) Starting Right Now
—Thursday, October 2, 2025
(ENVB) Comes Stacked By Several Potential Catalysts Like:
Limited Float: (ENVB) Has A Small Float Of Less Than 3.3M Shares Listed, Which Could Lead To The Potential For Big Moves If Demand Starts To Change.
Analyst Target: As Of October 2, Vernon Bernardino Of HC Wainwright Has A $10 Target On (ENVB), Which Suggests 1,400% Upside Potential.
Under The Radar: Still Trending Below $1, (ENVB) Has Not Landed On Most
Screens As It Remains In Discovery Mode For Most Readers.
Take A Look At (ENVB) Before The Bell Rings…
October 2, 2025
Early Window | Take A Look At (NASDAQ: ENVB) Before The Bell Rings Dear Reader, The clock is ticking—and for too many, the wait drags on while symptoms remain. Standard treatments can take weeks, sometimes with no lasting effect. This morning, one company just hit our radar: Enveric Biosciences (NASDAQ: ENVB)—developing next-gen, non-hallucinogenic compounds aimed at speed, durability, and everyday practicality. If you're seeing this, you're still early. Here's why (ENVB) is topping our watchlist this morning—October 2, 2025. Very Limited Float: With a small float of less than 3.3M shares listed as available for the public—(ENVB) has the potential to witness significant swings if demand begins to change.
Under The Radar: Still trending below $1, (ENVB) has not landed on most screens as it still appears to be in discovery mode for most readers. Analyst Target: As of yesterday, October 1, 2025, Vernon Bernardino of HC Wainwright has a $10 target on (ENVB) —which suggests 1,400% upside potential from its recent $.65 range. According to Benzinga, TipRanks, and MarketWatch, as of today, October 2, 2025, Vernon Bernardino of HC Wainwright has a $10 target on (ENVB)—which suggests over 1,400% upside potential from its recent $.65 range. 
With potential momentum building on the chart, it's still trending under $1, and analyst coverage, the real story lies beneath the surface—what this company is actually developing. Because behind the scenes is a bold plan to change the way mental health is treated—one that could set (ENVB) apart from nearly everything else in the space right now. On September 16, 2025, Enveric announced it had received a written response from the FDA regarding its lead program, EB-003. Instead of pausing for a pre-IND meeting, the FDA recommended the company proceed directly to IND submission, a shift that streamlines its regulatory path and sharpens the timeline toward clinical evaluation. Enveric expects to file the IND for EB-003 in early 2026—a pivotal milestone that positions the program one step closer to first-in-human study. 
Breaking the Cycle: ENVB's Next-Gen Approach to Mental Health
Enveric Biosciences (NASDAQ: ENVB) is working to change how difficult psychiatric conditions are treated. Instead of leaning on decades-old solutions, the company is developing next-generation compounds built to help the brain rewire itself—while avoiding the hallucinatory side effects that limit psychedelic-based therapies. Leading the pipeline is EB-003, a non-hallucinogenic, orally available candidate. Unlike current treatments that can take weeks to show effect—or trial-stage therapies that require hours of in-clinic supervision—EB-003 has been designed for convenience and speed, aiming to deliver fast, durable relief in a way that could fit into everyday life. What The Early Data Say—And Why It Matters
Early readouts are hard to ignore. In a validated PTSD model, a single oral dose of EB-003 reduced fear-conditioned responses; in depression testing, EB-003 delivered statistically significant improvements on standard behavioral measures. Just as important, the profile to date supports daily oral use, a practical edge over hallucinatory approaches that require infrequent, supervised sessions. Taken together, these signals point toward a path that could be both effective and workable in real-world care. Here's the simple idea behind it: EB-003 aims to upgrade the wiring and level the mood—helping the brain build healthier connections while keeping motivation and emotional tone on a steadier track. That dual action goes after deeper circuit balance, not just surface symptoms, which is why this approach could feel different from what's out there today. From Discovery To Pipeline: How Psybrary™ Feeds What's Next
(ENVB) isn't a one-program story. Its Psybrary™ platform is a proprietary engine for designing and refining new small molecules for psychiatric and neurological conditions. From that engine, the EVM-301 series explores novel tryptamine-based chemistry, while the EVM-401 series—recently strengthened by a second U.S. patent allowance—focuses on non-hallucinogenic mescaline-inspired derivatives with potential across PTSD, ADHD, and substance-related conditions. The company has also licensed earlier assets, creating more than one path to value from the pipeline. (ENVB)'s Recent Media Coverage
September 22, 2025: The Next Chapter in Ps-ych-ede-lic Medicine: How Enveric Biosciences Stands Apart — HoneySuckle
September 16, 2025: With big pharma circling ps-ych-ede-lics, the next breakthrough may not come from tripping at all — Micro-dose
August 28, 2025: AbbVie's $1B Ps-ych-ede-lic B-et: Who's Next in the Neuroplastogen Gold Rush? — Micro-dose
August 19, 2025: Reimagining Ps-ych-ede-lics: Mental Wellness Without the Roadblocks — Pharmaceutical Online
August 18, 2025: Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets — Micro-dose
August 14, 2025: The Future Of Psychedelic-Inspired Therapeutics: No-Trip Neuroplastogens — Life Science Leader
August 12, 2025: Six psychedelic drug companies aiming to revolutionize mental health treatment — Labiotech Bottom line: (ENVB) is shifting from niche to noticed, with coverage zeroing in on its practical, non-hallucinogenic strategy. Analysts See a $35B+ Neuroplastogen Market by 2030—(ENVB) Is Moving In Early
The gap in care is massive: roughly 65M people in the U.S. will face a serious psychiatric disorder over their lifetime, and nearly half don't respond to first-line antidepressants that can take 4–6 weeks to even start working. Enveric is building toward a faster, more practical approach that aims to fit real life for patients and clinicians. Analysts peg the global market for neuroplastogen-based treatments at $35B+ by 2030, and Enveric is moving early with a differentiated pipeline to meet that momentum. As of June 30, 2025, the company reported $2.8M in cash and $4.9M raised in net proceeds during the first half of the year to support progress. Near term, the focus is clear: complete the remaining IND-enabling work for EB-003 and submit a U.S. IND in early 2026—the gateway to first-in-human study. 
See additional sources: Company's Website & Corporate Presentation
7 Reasons Why (ENVB) Is Topping Our Watchlist This Morning
—Thursday, October 2, 2025
1. Very Limited Float: With a small float of less than 3.3M shares listed as available to the public, (ENVB) could have the potential for big moves if demand begins to shift. 2. Still Under The Radar: Trending below $1, (ENVB) has not appeared on most screens and continues to sit in discovery mode for many readers. 3. Analyst Target: As of today, October 2, 2025, HC Wainwright's Vernon Bernardino has a $10 target on (ENVB), which suggests over 1,400% upside potential from its recent range. 4. FDA Response: On September 16, 2025, (ENVB) announced the FDA recommended moving directly to IND submission for EB-003, streamlining its regulatory path. 5. Lead Program: EB-003, advanced by (ENVB), is designed as a non-hallucinogenic, orally available candidate aiming for faster onset and durable relief. 6. Pipeline Platform: Through its Psybrary™ discovery engine, (ENVB) is developing multiple series including EVM-301 and EVM-401, creating more than one path forward. 7. Media Recognition: Coverage from HoneySuckle, Microdose, Pharmaceutical Online, Life Science Leader, and Labiotech has spotlighted (ENVB)'s differentiated "no-trip" approach. Take A Look At (ENVB) Before The Bell Rings… With a very limited float, still trending under the radar, and backed by analyst coverage pointing toward a $10 target, (ENVB) is beginning to stand out. Recent FDA feedback has streamlined the path for its lead program, EB-003, while its Psybrary™ platform expands the pipeline across multiple fronts. Add in the steady media recognition spotlighting its differentiated "no-trip" approach, and it's clear why (ENVB) has moved to the forefront of our radar this morning. We will have all eyes on (ENVB) right now. Take a look at (ENVB) this morning before the bell rings. Also, keep a look out for my next update—it could be here any moment. Sincerely,
Gary Silver
Managing Editor, Market Crux
| 
Tidak ada komentar:
Posting Komentar